Banque Pictet & Cie Sa Uni Qure N.V. Transaction History

Banque Pictet & Cie Sa

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	SELL	$4.82 - $6.93 $59,787 - $85,959	-12,404 Reduced 8.58%	132,181 $687,000
Q4 2023 Feb 09, 2024	SELL	$5.63 - $8.27 $90,327 - $132,683	-16,044 Reduced 9.99%	144,585 $978,000
Q3 2023 Nov 02, 2023	SELL	$6.71 - $11.83 $50,116 - $88,358	-7,469 Reduced 4.44%	160,629 $1.08 Million
Q2 2023 Aug 04, 2023	SELL	$11.12 - $22.2 $714,348 - $1.43 Million	-64,240 Reduced 27.65%	168,098 $1.93 Million
Q1 2023 May 01, 2023	SELL	$18.7 - $23.07 $732,553 - $903,744	-39,174 Reduced 14.43%	232,338 $4.68 Million
Q4 2022 Feb 06, 2023	BUY	$18.12 - $27.32 $2.9 Million - $4.37 Million	159,980 Added 143.44%	271,512 $0
Q3 2022 Nov 10, 2022	SELL	$16.98 - $25.54 $7,029 - $10,573	-414 Reduced 0.37%	111,532 $2.09 Billion
Q2 2022 Aug 08, 2022	BUY	$13.15 - $20.45 $432,700 - $672,907	32,905 Added 41.63%	111,946 $2.09 Million
Q1 2022 May 04, 2022	BUY	$14.54 - $21.5 $44,477 - $65,768	3,059 Added 4.03%	79,041 $1.43 Million
Q4 2021 Feb 02, 2022	BUY	$20.24 - $36.01 $1.54 Million - $2.74 Million	75,982 New	75,982 $1.58 Million

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Banque Pictet & Cie Sa, based on Form 13F filings with the SEC.

Stay updated on Banque Pictet & Cie Sa with notifications on news.